Literature DB >> 27330343

Provincial elections and timing of cancer drug funding.

A Srikanthan1, S S Gill2, K K W Chan3.   

Abstract

BACKGROUND: Concerns have been raised about the potential influence of political pressures on drug funding decisions. We evaluated the temporal relationship between cancer drug funding and provincial elections in 9 Canadian provinces.
METHODS: New indications for cancer drugs between January 2003 and December 2012 were identified, and the dates of official provincial funding dates and election dates between 1 January 2003 and 31 December 2014 were retrieved. The probability of drug funding announcements in the 60-day period preceding a provincial election was evaluated using binomial probability distribution analysis.
RESULTS: Data from 9 provinces (all Canadian provinces except Quebec) were available. During the period of interest, 69 new indications for 39 individual drugs were identified. Variation in the availability of funding dates was identified. At the time of data collection, 2 provinces did not have data available for all 69 indications. For the 9 provinces, the number of funded indications during the 60-day period preceding an election ranged from 0 to 3; however, no differences in the proportion of indications funded pre-election were identified. Additional analyses also failed to demonstrate any significant associations with the 90-day period before an election, or the 60- and 90-day periods after an election.
CONCLUSIONS: We observed no clear temporal relationship between provincial election dates and funding decisions in this recent Canadian sample of new indications for cancer drugs.

Entities:  

Keywords:  Cancer drugs; drug funding; elections; politics

Year:  2016        PMID: 27330343      PMCID: PMC4900826          DOI: 10.3747/co.23.3024

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  11 in total

Review 1.  The politics of public health policy.

Authors:  Thomas R Oliver
Journal:  Annu Rev Public Health       Date:  2006       Impact factor: 21.981

2.  Drugs, sex, money and power: an HPV vaccine case study.

Authors:  Marion Haas; Toni Ashton; Kerstin Blum; Terkel Christiansen; Elena Conis; Luca Crivelli; Meng Kin Lim; Melanie Lisac; Margaret Macadam; Sophia Schlette
Journal:  Health Policy       Date:  2009-06-07       Impact factor: 2.980

3.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

Authors:  Fiona M Clement; Anthony Harris; Jing Jing Li; Karen Yong; Karen M Lee; Braden J Manns
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

Review 4.  Perspectives of commissioners and cancer specialists in prioritising new cancer drugs: impact of the evidence threshold.

Authors:  R Foy; J So; E Rous; J H Scarffe
Journal:  BMJ       Date:  1999-02-13

5.  Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.

Authors:  Green Bae; Eun Young Bae; SeungJin Bae
Journal:  Health Policy       Date:  2015-01-23       Impact factor: 2.980

6.  Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.

Authors:  J S Hoch; M Sabharwal
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

7.  Priority-setting decisions for new cancer drugs: a qualitative case study.

Authors:  D K Martin; J L Pater; P A Singer
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

8.  American Society of Clinical Oncology guidance statement: the cost of cancer care.

Authors:  Neal J Meropol; Deborah Schrag; Thomas J Smith; Therese M Mulvey; Robert M Langdon; Diane Blum; Peter A Ubel; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2009-07-06       Impact factor: 44.544

Review 9.  External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Authors:  Christopher M Booth; George Dranitsaris; M Corona Gainford; Scott Berry; Michael Fralick; John Fralick; Joanna Sue; Mark Clemons
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

10.  The timing of drug funding announcements relative to elections: a case study involving dementia medications.

Authors:  Sudeep S Gill; Neeraj Gupta; Chaim M Bell; Paula A Rochon; Peter C Austin; Andreas Laupacis
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more
  2 in total

1.  Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.

Authors:  A Srikanthan; N Penner; K K W Chan; M Sabharwal; A Grill
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

2.  Determinants of the Cancer Drug Funding Process in Canada.

Authors:  Joanna Gotfrit; Ashley Jackson; John J W Shin; David J Stewart; Ranjeeta Mallick; Paul Wheatley-Price
Journal:  Curr Oncol       Date:  2022-03-15       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.